Dr. Reddy’s Laboratories Limited commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas. The company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and on the New York Stock Exchange in the United States.
Business area of the company
The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations.
Pharmaceutical services & active ingredients
Global leader in integrated development, manufacturing and supply of APIs.
Contract research, development and manufacturing services.
Finished dosage businesses in distribution-driven unbranded as well as detailing-driven branded markets.
North America, Europe, India, China, Russia & CIS countries are key markets in this segment.
Awards & Recognitions
India’s Best Managed Boards by Mint and Aon Hewitt and by Economic Times and Hays in their respective studies.
India’s Best Companies to Work For in the Biotechnology and Pharmaceuticals sector by Great Place To Work Institute.
‘Best Places to Work’ in 2017 in New Jersey by NJBIZ.
Global Generics & Biosimilar Award 2018 for CSR initiative of the year
India Pharma Corporate Social Responsibility (CSR) programme of the year Award 2018 by Department of Pharmaceuticals, Government of India.
Dr. Reddy’s ranked among the top 10 in the Forbes China 2018 list of leading Indian Companies in China.
Dr. Reddy’s inclusion in the 2019 Bloomberg Gender-Equality Index.
Global Generics & Biosimilars Award 2019: API supplier of the Year at the 6th Annual Global Generics & Biosimilars Awards.
Winner of Golden Peacock International Award for Sustainability for the year 2019.
1984: The birth of a dream
1991: From molecules to affordable medicines
1995: Expanding to reach patients in other countries
2001: Spreading wings globally
2007: Accelerating access to expensive therapies
2010: From medicines to health
2012: Strengthening capabilities
2014: Re-dedicating to patient-centricity
2015: Dr. Reddy’s Laboratories signs commercialization deal with Hatchtech
2016: Dr. Reddy’s completes acquisition of product portfolio from TEVA
2017: Dr. Reddy's expands commercial operations in Europe
2018: Dr. Reddy's Laboratories announces the launch of Tetrabenazine Tablets in the U.S. Market
2019: Dr. Reddy’s Laboratories enters Nutrition Segment with Celevida in India
2020: Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets